Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CITADEL-123: 123I-ATT001 in Relapsed Glioblastoma
NCT06650605Phase 1Completed
- Sponsor
- Theragnostics
- Start
- Jul 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ATT001 in glioblastoma (GBM), sponsored by Theragnostics. Primary endpoints: Frequency and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) and Incidence of Dose Limiting Toxicity (DLT) at Day 14. Started Jul 2024; status: completed.
02
Drugs
ATT001
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06650605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06650605.